Welcome to our dedicated page for EAGLE PHARMS news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on EAGLE PHARMS stock.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) is a leading specialty pharmaceutical company committed to the development and commercialization of innovative injectable products targeted at critical care, orphan diseases, and oncology. The company’s robust portfolio includes four FDA-approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. Eagle is also advancing multiple product candidates through late-stage development, with several under review by the Food and Drug Administration (FDA).
Recently, Eagle achieved a significant regulatory milestone with its product Barhemsys® (amisulpride) injection. On January 1, 2024, Barhemsys will receive a unique, product-specific billing code (J-0184) from the Centers for Medicare & Medicaid Services (CMS), facilitating better access and separate reimbursement for the drug outside of surgical bundled payments. Barhemsys is the only FDA-approved medication for treating postoperative nausea and vomiting (PONV) in patients who have failed PONV prophylaxis, addressing a critical unmet medical need.
In addition to its marketed products, Eagle Pharmaceuticals boasts an extensive pipeline focusing on oncology and CNS/metabolic critical care. Noteworthy among these is the ready-to-dilute formulation of Pemfexy, used in treating non-small cell lung cancer and malignant pleural mesothelioma. Pemfexy's unique J-Code from CMS has earned it a 24% share in the non-340B pemetrexed market, reflecting its commercial success and innovation.
Financially, Eagle remains strong, with steady revenues from its commercialized products and a commitment to reporting accurate financial results. While the company has revised its 2023 guidance downward, it remains confident in the outlook for 2024, backed by ongoing development and new initiatives.
This strategic focus is further reinforced by Eagle’s robust intellectual property protections and recent litigation successes. The company is actively defending its patents against generic competitors, ensuring the continued commercial viability of its flagship products, Bendeka and Belrapzo.
With a team of dedicated professionals in research, development, clinical, and commercial operations, Eagle Pharmaceuticals is poised to make significant strides in the pharmaceutical industry. For the latest news and updates, visit their official website at www.eagleus.com.
Eagle Pharmaceuticals (EGRX) has announced key developments for 2022, including the launch of its vasopressin product on January 17, 2022, which comes with 180 days of marketing exclusivity. The company also plans to launch PEMFEXY on February 1, 2022, targeting a U.S. market valued at $1.2 billion. Additional pipeline advancements include human studies for fulvestrant, NDA submission for Landiolol, and clinical trials for CAL02. Eagle expects significant revenue growth driven by these initiatives, alongside a strong balance sheet to support strategic decisions.
Eagle Pharmaceuticals (EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 4:30 PM ET. The presentation will be held virtually, and interested parties can access the webcast here. The webcast will remain available for 30 days on the company’s website, under the Investors section.
Eagle Pharmaceuticals specializes in developing innovative medicines with a strong pipeline in oncology and CNS/metabolic critical care.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) announced that the FDA has confirmed the company’s 180 days of marketing exclusivity for its approved abbreviated new drug application (ANDA) for vasopressin. In August, a favorable ruling from the U.S. District Court for Delaware determined that Eagle's vasopressin product does not infringe any patents asserted by Par Pharmaceutical, although an appeal is pending. CEO Scott Tarriff expressed optimism about the 2022 launch of both vasopressin and PEMFEXY™ starting February 1, 2022.
Eagle Pharmaceuticals, Inc. (EGRX) announced that Par Pharmaceutical, Inc. has withdrawn its request for a temporary restraining order against the launch of Eagle's vasopressin product. This follows a ruling by the U.S. District Court in Delaware on August 31, 2021, stating that the product does not infringe Par's asserted patents. Eagle's CEO, Scott Tarriff, expressed optimism regarding their launch plans for the vasopressin product.
Eagle Pharmaceuticals, Inc. (EGRX) announced FDA approval for its abbreviated new drug application (ANDA) for vasopressin, positioning it as a generic alternative to Vasostrict®, which generated $786 million in U.S. sales in 2020. This approval follows a favorable court ruling that confirmed no patent infringement by Eagle. With an anticipated 180-day marketing exclusivity, the company aims to enhance its critical care portfolio, which is crucial for patients and healthcare providers. The launch plans for vasopressin are now being implemented.
Eagle Pharmaceuticals (NASDAQ: EGRX) announced that CEO Scott Tarriff and CFO Brian Cahill will present at the Piper Sandler 33rd Annual Healthcare Conference on November 22, 2021, at 10:00 AM ET. Attendees can access the on-demand webcast via the company's website for 90 days post-event. Additionally, Eagle will hold one-on-one meetings on December 1, 2021, which must be requested through Piper Sandler. Eagle focuses on developing innovative medicines and has products including RYANODEX®, BENDEKA®, and BELRAPZO®.
Eagle Pharmaceuticals reported a Q3 2021 net loss of $5.6 million, or $0.43 per share, a decline from a net income of $7.1 million in Q3 2020. Total revenue decreased to $39.9 million, down from $49.9 million year-over-year, primarily due to lower sales of BELRAPZO and BENDEKA. Adjusted non-GAAP net income was $7.5 million, down from $16.1 million in the previous year. Eagle is preparing for key product launches, including vasopressin and PEMFEXY, and secured a worldwide licensing agreement for CAL02, an antitoxin agent ready for Phase 2b/3 development.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) will release its 2021 third quarter financial results on November 9, 2021, before the market opens. CEO Scott Tarriff and CFO Brian Cahill will host a conference call on the same day at 8:30 a.m. ET to discuss the results. Investors can access the call via a toll-free U.S. number or internationally, as well as through a live and archived webcast available on the company's website. Eagle Pharmaceuticals is dedicated to innovative medicine development, with a portfolio including RYANODEX® and BENDEKA®.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) will host an investor event on September 9, 2021, at 8:30 A.M. EDT. Led by CEO Scott Tarriff and CMO Judi Ng-Cashin, the event will discuss the CAL02 opportunity and the current landscape for treating severe pneumonia. CAL02 is an innovative drug that targets bacterial toxins, potentially reducing complications in pneumonia patients without contributing to antibiotic resistance. Additional details, including a webcast link, are available on the company’s website.
Eagle Pharmaceuticals, Inc. (EGRX) has announced that CEO Scott Tarriff and CFO Brian Cahill will present at two upcoming investor conferences. The first is the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, at 2:00 p.m. ET, with a live webcast available here. The second conference is the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 4:40 p.m. ET, with a live webcast available here.
FAQ
What is the current stock price of EAGLE PHARMS (EGRX)?
What is the market cap of EAGLE PHARMS (EGRX)?
What products does Eagle Pharmaceuticals offer?
What recent regulatory updates have impacted Eagle Pharmaceuticals?
What areas does Eagle Pharmaceuticals focus on?
How is Eagle Pharmaceuticals performing financially?
What is Pemfexy used for?
What distinguishes Barhemsys in the market?
What is Eagle Pharmaceuticals' approach to intellectual property?
What is the focus of Eagle Pharmaceuticals' pipeline?
How can I stay updated on Eagle Pharmaceuticals' latest news?
What is the impact of Eagle's litigation efforts?
